Interstitial Lung Disease Trial, Recruiting NCT06570317 Sponsor: Second Hospital of Shanxi Medical University Condition: Interstitial Lung Disease
Back to Interstitial Lung Disease

Interstitial Lung Disease Trial, Recruiting

NCT06570317
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older at the time of signing the consent form
  • People with non-small cell lung cancer confirmed by tissue testing, where the cancer cannot be surgically removed, and where testing has confirmed that the EGFR and ALK gene mutations are not present
  • People who have at least one measurable tumour, measuring 10mm or more in its longest dimension, visible on a CT or MRI scan
  • People whose physical functioning was assessed as good (scoring 0 or 1 on a standard performance scale) within 3 days before starting treatment
  • People with a life expectancy of at least 3 months
  • People whose major organs (such as heart, lungs, liver, and kidneys) are functioning adequately
  • People who are willing to participate, have signed the consent form, and are able to cooperate with follow-up visits

Who may not be able to join:

  • People who have serious breathing-related conditions such as pulmonary fibrosis or active tuberculosis
  • People with mental health disorders, blood system diseases, autoimmune diseases, or serious existing conditions affecting the heart, brain, liver, or kidneys
  • People who experienced a significant bleeding event requiring a blood transfusion, a medical procedure, or hospitalisation in the 3 months before the first dose — or who currently have bleeding symptoms or factors that may raise the risk of bleeding, such as a tumour near major blood vessels, significant tumour tissue breakdown, or enlarged veins in the oesophagus
  • People with blood clotting disorders, a history of blood clots or blockages in blood vessels, or a tendency to bleed
  • People with a known or suspected allergy to the study drug or any of its ingredients
  • Women who are pregnant, breastfeeding, or who are of childbearing potential and have returned a positive pregnancy test at the start of the study
  • People who, in the opinion of the research team, have other circumstances that may make completing the study unsafe or unsuitable (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Gang Jin, Dr., Second Hospital of Shanxi Medical University

Phone: +86 351 3365422

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Second Hospital of Shanxi Medical University
Registry
ClinicalTrials.gov
Start date
24 August 2024
Est. completion
31 May 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

security; Incidence rate of radiation pneumonia

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov